Velneva’s Clostridium difficile vaccine Candidate meets Phase II trial target

Valneva SE, a pure-play vaccine company, has announced positive Phase II results for its prophylactic vaccine candidate against Clostridium difficile (C. difficile) infection (CDI).

The key objectives of this Phase II trial have been met, the vaccine candidate generated strong immune responses against C. difficile toxins A and B, and the safety and tolerability profile was good.

Valneva`s vaccine candidate is targeting the prevention of primary symptomatic C.difficile infection (CDI). The vaccine is designed to produce an immune response to neutralize the effects of C. difficile toxins A and B, considered to be largely responsible for CDI, which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide.

Thomas Lingelbach, President and CEO and Franck Grimaud, Deputy CEO of Valneva, commented, “C. difficile has become the most frequent hospital-acquired infection and is now linked to almost 30 thousand deaths every year in the US alone[1]. Our Phase II results provide a strong basis for the further development of a much needed vaccine for the prevention of C. difficile infection (CDI) in a growing target population of older patients”